Granules India Ltd - Company Profile
Powered by 
All the data and insights you need on Granules India Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Granules India Ltd Strategy Report
- Understand Granules India Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Granules India Ltd (Granules) is a pharmaceutical manufacturing company, that manufactures active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs) and finished dosages (FDs). The company manufactures Ibuprofen, Paracetamol, Metformin, Guaifenesin and Methocarbamol. It has premier facilities for the manufacture of APIs, PFIs and FDs. With offices in India, the US, and the UK, the company offers products and solutions to over 80 countries across the world. Granules also provides contract research and manufacturing services. The company's key clients include generic and branded pharmaceutical companies. Granules is headquartered in Hyderabad, Telangana, India.
Headquarters
India
Address
2nd Floor, 3rd Block, My Home Hub Madhapur, Hyderabad, Telangana, 500081
Website
granulesindia.com
Telephone
91 40 69043500
No of Employees
3,650
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GRANULES (NSE)
Revenue (2023)
$575.0M
19.8%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
25.2%
(2023 vs 2022)
Market Cap*
$1.2B
Net Profit Margin (2023)
XYZ
4.5%
(2023 vs 2022)
* As of and is in US$
Granules India Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Caplets | Customized Packaging | COLCRYS |
| Capsules | Contract Manufacturing Services | Allegra |
| Tablets | Neurontin | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In December, the company secured approval from the US Food & Drug Administration for Pantoprazole Sodium Delayed-Release Tablets USP, 20 mg and 40 mg. |
| 2023 | Regulatory Approval | In August, the company announced that the US Food and Drug Administration approved its Abbreviated New Drug Application for Metoprolol Succinate ER Tablets 25/50/100/200 mg. |
| 2023 | Regulatory Approval | In August, the company secured an the approval from Brazilian Health Regulatory Agency for compliance with the guidelines of Good Manufacturing Practices for its Bonthapally facility. |
Competitor Comparison
| Key Parameters | Granules India Ltd | Teva Pharmaceutical Industries Ltd | Biocon Ltd | Divi's Laboratories Ltd | Atul Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Israel | India | India | India |
| City | Hyderabad | Tel Aviv | Bangalore | Hyderabad | Ahmedabad |
| State/Province | Telangana | Tel Aviv | Karnataka | Telangana | Gujarat |
| No. of Employees | 3,650 | 35,001 | 3,408 | 16,950 | 3,188 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Krishna Prasad Chigurupati | Managing Director; Chairman | Executive Board | 2019 | 69 |
| K.V.S Ram Rao | Chief Executive Officer; Director; Joint Managing Director | Executive Board | 2022 | - |
| Mukesh Surana | Chief Financial Officer | Senior Management | 2022 | - |
| P. V. Srinivas | Chief Technology Officer | Senior Management | - | - |
| Atul Dhavle | Chief Human Resources Officer | Senior Management | 2024 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward